The Changing Landscape of Preventive Treatment of Migraine

Andrew C. Charles, MD, provides a historical perspective on the agents traditionally used for preventive migraine therapy.

Expert neurologists share their goals and patient considerations for preventive migraine therapy.

Key opinion leaders explain the burden of disease that accompanies preventative migraine treatment.

A discussion on how to measure the success of preventative migraine treatment.

Rebecca Erwin Wells, MD, MPH, details the effectiveness of lifestyle changes for preventative migraine treatment.

Dr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.

An expert panel discusses migraine prevention with the use of behavioral therapies such as cognitive behavioral therapy and stress management.

An introduction to the use of novel agents for preventive migraine therapy.

A thought leader explains how she involves the patient when selecting novel agents to add to a preventive migraine treatment plan.

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, provides an overview of the use of onabotulinumtoxinA as a preventive migraine treatment.

Expert neurologists discuss the use of CGRP monoclonal antibodies to prevent migraines.

A panel of neurologists review clinical trial data on several CGRP monoclonal antibodies for migraine preventive treatment.

Dr Christopher Gottschalk shares how the clinical trial data for CGRP monoclonal antibodies affect patient selection for preventive migraine treatment.

A key opinion leader discusses the use of oral agents for the preventive treatment of migraine.

Jessica Ailani, MD, details how the phase 3 ADVANCE trial will shape the research of future agents for preventive migraine treatment.

A discussion on when a patient should be referred to a headache specialist for preventive migraine treatment.

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.